There’s a large class of viable pharmaceuticals which don’t see the light of day because their unpatentability causes companies not to fund the clinical trials which would be necessary to clear regulatory approval.
Could you cite any? Or at least point me at some research/source on the subject?
There’s a large class of viable pharmaceuticals which don’t see the light of day because their unpatentability causes companies not to fund the clinical trials which would be necessary to clear regulatory approval.
Could you cite any? Or at least point me at some research/source on the subject?